• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OXYCODONE Drug Record

  • Summary
  • Interactions
  • Claims
  • OXYCODONE chembl:CHEMBL656

    Alternate Names:

    N02AA05
    IDS-NO-002
    NSC-19043
    OXICONE
    PF-00345439
    XTAMPZA ER
    PTI-821
    OXYCONTIN
    OXYCODONE CII
    PROLADONE
    OXYCODONE
    pubchem.compound:5284603
    4,5Α-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE
    4,5ALPHA-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE
    OXYCODONE HYDROCHLORIDE
    DIHYDROXYCODEINONE
    OXYCODONUM
    ROXICODONE®
    OXICODONA
    DIHYDRO-14-HYDROXYCODEINONE
    DIHYDROHYDROXYCODEINONE
    (-)-14-HYDROXYDIHYDROCODEINONE
    4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE
    chembl:CHEMBL656
    drugbank:00497
    chemidplus:76-42-6
    rxcui:7804

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications analgesic
    Drug Class analgesics, opioid
    Year of Approval 1939
    (3 More Sources)

    Publications:

    Pu J et al., 2019, Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer., Eur Rev Med Pharmacol Sci
    Cajanus K et al., 2014, How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism., J Pain
    Naito T et al., 2011, CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone., J Clin Pharmacol
    Ordóñez Gallego et al., 2007, Oxycodone: a pharmacological and clinical review., Clin Transl Oncol
    Riley et al., 2008, Oxycodone: a review of its use in the management of pain., Curr Med Res Opin
    Dietis et al., 2009, Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile., Br J Anaesth
    Li J et al., 2018, The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin., Support Care Cancer
    Hassan HE et al., 2013, Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone., Drug Metab Dispos
    Aubrun F et al., 2018, Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study., Eur J Anaesthesiol
    Matic M et al., 2017, Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement., Pharmacogenomics
    Hronová K et al., 2016, Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome., Physiol Res
    Elens L et al., 2016, Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation., Ther Drug Monit
    De Gregori M et al., 2016, Human Genetic Variability Contributes to Postoperative Morphine Consumption., J Pain
    Candiotti KA et al., 2014, Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain., Anesth Analg
    Matic M et al., 2014, Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype., Pharmacogenomics
    Cargnin S et al., 2013, An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans., J Pain
    De Gregori M et al., 2013, Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain., Eur J Clin Pharmacol
    Landau R et al., 2013, The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia., Anesth Analg
    Klepstad P et al., 2011, Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients., Pain
    Lötsch J et al., 2009, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers., Pharmacogenet Genomics
    Oosten AW et al., 2016, Opioid treatment failure in cancer patients: the role of clinical and genetic factors., Pharmacogenomics
    Nielsen et al., 2007, Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain., Pain
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Galvan A et al., 2011, Multiple Loci modulate opioid therapy response for cancer pain., Clin Cancer Res
  • OXYCODONE   RHBDF2

    Interaction Score: 4.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21622719


    Sources:
    PharmGKB

  • OXYCODONE   COMT

    Interaction Score: 2.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130


    Sources:
    PharmGKB

  • OXYCODONE   OPRD1

    Interaction Score: 1.01

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name COL-003, sustained release oxycodone
    Novel drug target Established target
    Trial Name COL-172, extended-release oxycodone

    PMIDs:
    17525040 11752352


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • OXYCODONE   NR1I3

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23439660


    Sources:
    DTC

  • OXYCODONE   OPRK1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name transdermal oxycodone
    Trial Name PTI-801,Oxytrex
    Trial Name oxycodone, PTI-821,Remoxy

    PMIDs:
    27472837 17467904 17525040 18039433


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • OXYCODONE   OPRM1

    Interaction Score: 0.66

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name COL-003, sustained release oxycodone
    Novel drug target Established target
    Trial Name PTI-801,Oxytrex

    PMIDs:
    31773688 25239082 21209234 17525040 18039433 19474215


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • OXYCODONE   UGT2B7

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29502154


    Sources:
    PharmGKB

  • OXYCODONE   CYP3A5

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21209234 18695978


    Sources:
    PharmGKB

  • OXYCODONE   ABCB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21209234 19514130


    Sources:
    PharmGKB

  • TEND: OXYCODONE

    • Version: 01-August-2011

    Alternate Names:
    OXYCODONE Primary Drug Name

    Drug Info:
    Year of Approval 1939
    Drug Class analgesics, opioid

    Publications:

  • TdgClinicalTrial: OXYCODONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: OXYCODONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL656 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hassan HE et al., 2013, Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone., Drug Metab Dispos

  • PharmGKB: oxycodone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Naito T et al., 2011, CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone., J Clin Pharmacol
    Lötsch J et al., 2009, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers., Pharmacogenet Genomics
    Cajanus K et al., 2014, How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism., J Pain

  • TTD: Oxycodone

    • Version: 2020.06.01

    Alternate Names:
    D03SKD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL656

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL656

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21